NYU Langone's Neurologists Share Groundbreaking Research at AAN 2025

From April 5 to April 9, 2025, experts from NYU Langone’s Department of Neurology showcased their latest clinical findings and research at the American Academy of Neurology (AAN) Annual Meeting held in San Diego. This event served as a platform for neurologists to discuss advancements in the field, including treatment strategies for stroke, Alzheimer's disease therapy, and the management of optic neuritis.

One key presentation focused on the management of blood pressure in patients with intracerebral hemorrhage (ICH), a type of stroke where blood leaks into the brain. Dr. Kara R. Melmed, a clinical associate professor at NYU Grossman School of Medicine, led discussions around the optimal blood pressure targets following acute treatment in ICH cases. Current guidelines suggest that while acute blood pressure reduction below 150 mm Hg is safe, dropping below 130 mm Hg could potentially be harmful. Dr. Melmed emphasized the pressing need for improved emergency care for hemorrhagic stroke patients, noting that many receive treatments much later compared to patients with acute ischemic strokes, consequently impacting survival rates.

Additionally, advancements in Alzheimer's treatment were highlighted, particularly through research on the drug lecanemab, known as Leqembi. A study revealed that early cognitive decline in patients undergoing treatment exhibited a slower progression compared to historical data, although side effects such as brain swelling in some individuals were reported. Dr. Philip Kuball, a resident in the Department of Neurology, noted that staying vigilant regarding patient criteria prior to treatment is crucial for subsequent outcomes.

Another critical area of investigation was the management of optic neuritis, a condition often linked with multiple sclerosis (MS) that leads to sudden vision loss. Dr. Steven L. Galetta, a neuro-ophthalmologist and department chair, shared insights into current diagnostic and treatment approaches. He noted the necessity of incorporating optic nerve assessments into MS diagnostic criteria, advocating for improved treatment methods to mitigate long-term visual impairments associated with optic neuritis.

In a notable seminar, Dr. Lauren B. Krupp discussed pediatric multiple sclerosis from a holistic perspective. Highlighting environmental and socioeconomic influences, she emphasized that early diagnosis and comprehensive treatment strategies, including lifestyle modifications, are vital for improving outcomes in younger MS patients. Her research points to a higher risk of severe MS indicators stemming from factors such as impoverished neighborhood conditions and early exposure to viral infections.

NYU Langone Health prides itself on being at the forefront of neurological advancements, consistently ranked among the best in the nation. Its commitment to research and innovative patient care practices ensures the continual evolution of therapies and management strategies aimed at improving neurological health outcomes. As part of the AAN 2025 Annual Meeting, nearly 70 presentations showcased the vast expertise within the NYU Langone’s neurology faculty, reflecting a shared dedication to pushing the boundaries of neurological science.

The outcomes of these studies not only further the understanding of neurological disorders but also pave the way for future innovations aimed at enhancing patient care and treatment efficacy. As the meeting concluded, faculty members expressed pride in their contributions to the field and the institution's support in driving forward revolutionary research and practices in neurology.